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1. Introduction
This document is a summary statement of the outcome from the meeting: “Bisphenol A: An
Examination of the Relevance of Ecological, In vitro and Laboratory Animal Studies for
Assessing Risks to Human Health” sponsored by both the NIEHS and NIDCR at NIH/DHHS,
as well as the US-EPA and Commonweal on the estrogenic environmental chemical bisphenol
A (BPA, 2,2-bis(4-hydroxyphenyl)propane; CAS# 80-05-7). The meeting was held in Chapel
Hill, NC, 28–30 November 2006 due to concerns about the potential for a relationship between
BPA and negative trends in human health that have occurred in recent decades. Examples
include increases in abnormal penile/urethra development in males, early sexual maturation in
females, an increase in neurobehavioral problems such as attention deficit hyperactivity
disorder (ADHD) and autism, an increase in childhood and adult obesity and type 2 diabetes,
a regional decrease in sperm count, and an increase in hormonally mediated cancers, such as
prostate and breast cancers. Concern has been elevated by published studies reporting a
relationship between treatment with “low doses” of BPA and many of theses negative health
outcomes in experimental studies in laboratory animals as well as in vitro studies identifying
plausible molecular mechanisms that could mediate such effects. Importantly, much evidence
suggests that these adverse effects are occurring in animals within the range of exposure to
BPA of the typical human living in a developed country, where virtually everyone has
measurable blood, tissue and urine levels of BPA that exceed the levels produced by doses
used in the “low dose” animal experiments.
Issues relating to BPA were extensively discussed by five panels of experts prior to and during
the meeting, and are summarized in five reports included in this issue: (1) human exposure to
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bisphenol A (BPA) [1]; (2) in vitro molecular mechanisms of bisphenol A action [2]; (3) in
vivo effects of bisphenol A in laboratory animals [3]; (4) an ecological assessment of bisphenol
A: evidence from comparative biology [4]; (5) an evaluation of evidence for the carcinogenic
activity of bisphenol A [5]. Further discussion occurred at the meeting where participants from
the panels were reorganized into four breakout groups. The consensus statements from the
meeting are presented below.
The definition of “low dose” of BPA at this meeting used the same two criteria established at
a prior NIH meeting concerning the low dose endocrine disruptor issue [6]: (1) for laboratory
animal studies “low doses” involved administration of doses below those used in traditional
toxicological studies conducted for risk assessment purposes. For BPA the lowest dose
previously examined for risk assessment purposes was 50 mg (kg−1 day−1) in studies with rats
and mice. The 50 mg (kg−1 day−1) dose is the currently accepted lowest adverse effect level
(LOAEL) that was used to calculate the current US-EPA reference dose (the daily dose that
EPA calculates is safe for humans over the life-time) of 50 µg (kg−1 day−1). The current
reference dose is thus based on “high dose” experiments conducted in the 1980s [7]. (2) “Low
dose” also refers to doses within the range of typical human exposure (excluding occupational
exposures). For purposes of this meeting, the published literature that was reviewed met both
of these criteria for being considered within the “low dose” range.
Hundreds of in vitro and in vivo studies regarding the mechanisms and effects of low doses of
BPA, as well as studies of biomonitoring and sources of exposure, have been published in peer
reviewed journals over the last 10 years, since the first “low dose” BPA in vivo studies were
published [8–10]. The meeting was convened specifically to integrate this relatively new
information. This task required the combined expertise of scientists from many different
disciplines, and care was taken to ensure that participants covered these diverse areas.
BPA is a high-volume (>6 billion pounds per year) production chemical used to make resins
and polycarbonate plastic [11]. Of particular concern is the use of BPA in food and beverage
plastic storage and heating containers and to line metal cans. In addition, potential
environmental sources of BPA contamination are due to use in dental fillings and sealants
[12], losses at the production site [13], leaching from landfill [14,15], and presence in indoors
air [16].
BPA has become a chemical of “high concern” only in recent years, even though BPA was
shown to stimulate the reproductive system in female rats and thus to be an “environmental
estrogen” in 1936 [17], long before it was used as the monomer to synthesize polycarbonate
plastic and resins in the early 1950s. However, more recent evidence has shown that BPA also
exhibits other modes of endocrine disruption in addition to binding to estrogen receptors, such
as alterations in endogenous hormone synthesis, hormone metabolism and hormone
concentrations in blood. BPA also results in changes in tissue enzymes and hormone receptors,
and interacts with other hormone-response systems, such as the androgen and thyroid hormone
receptor signaling systems. While BPA was initially considered to be a “weak” estrogen based
on a lower affinity for estrogen receptor alpha relative to estradiol [18], research shows that
BPA is equipotent with estradiol in its ability to activate responses via recently discovered
estrogen receptors associated with the cell membrane [19–22]. It is through these receptors
that BPA stimulates rapid physiological responses at low picogram per ml (parts per trillion)
concentrations.
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2. Purpose and organization of the BPA meeting
2.1. Topic-focused expert panels
To address the strength of the evidence regarding the published BPA research, an organizing
committee was formed, and five panels of experts from different disciplines were established.
Each panel had a chair or co-chairs and included a scientist who agreed to be primarily
responsible, along with the chair, for preparing a preliminary draft of the panel’s report. A web
site was established on which all of the available electronic files of articles concerning BPA
were posted, along with other pertinent information relating to the meeting. Prior to the
meeting, the panel members began working on draft reports and communicated via electronic
media and telephone conference calls. The resulting preliminary report from each panel was
posted on the web site and distributed at the meeting for all participants to read. After the
meeting, each panel completed a manuscript that is a part of this meeting report. These five
panel reports were peer reviewed using the normal manuscript submission process to
Reproductive Toxicology.The following specific concerns about BPA led to the five expert
panels being established:
1. Leaching of BPA occurs from the resin lining of metal cans and from plastic food and
beverage containers under conditions of normal use. BPA is also detected in water
and air samples.
2. Parts per billion (ppb) levels of BPA that are unconjugated (not metabolized and thus
biologically active) are detected in human blood and tissues in different countries,
and these levels appear to be higher than blood levels that would be present in animals
exposed to the US-EPA reference dose.
3. BPA causes a wide range of adverse effects at “low doses” that are below the US-
EPA reference dose in animals, both terrestrial and aquatic.
4. There is evidence from in vitro mechanistic studies that indicates the potential for
disruption of human and animal cell function at concentrations of BPA far below
unconjugated levels typically found in human blood and tissues.
5. There is evidence that at very low doses, BPA may be carcinogenic or increase
susceptibility to cancer in animals.
The five panels each addressed a different topic related to their specific area of expertise with
BPA and prepared a panel report that included documentation of the relevant published studies:
Panel (1)Sources and amounts of human exposure to BPA as well as pharmacokinetics.
Panel (2)In vitro studies related to the molecular mechanisms that mediate responses to BPA
with an emphasis on studies using low doses.
Panel (3)In vivo studies of BPA at “low doses” in laboratory animals.
Panel (4)In vivo studies of BPA in aquatic wildlife and laboratory animals.
Panel (5)Relationship of BPA to cancers.
The purpose of the 3-day meeting was to provide an opportunity for members of the different
panels to interact with each other to integrate information from different disciplines concerning
low dose effects of BPA after each panel of experts had prepared a report in its specific area.
The agenda of the meeting was designed to allow the members of the five panels to have time
to discuss the information in their panel reports and finalize statements about the strength of
the evidence for the literature that the panel had reviewed.
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2.2. Integration of information by breakout groups
For the second part of the meeting the focus was on integrating the information from each of
the panel reports. This was accomplished by assigning panel members to one of four breakout
groups. The four replicate breakout groups were established using the following criteria, such
that each breakout group should have
1. At least two members from each of the five panels.
2. A person from each panel who had published on BPA.
3. A person with general knowledge of endocrine disruption research or endocrinology,
but who had not necessarily published on BPA.
4. A person with experience in the process of reaching consensus.
5. A mixture of junior and senior investigators.
The charge to the replicate breakout groups was to individually integrate the information
relating to the following four issues:
Issue (1)Determine the degree to which the findings on BPA mechanisms of action identify
mechanisms and bioactive doses that explain results of the studies reported by the
panel on in vivo laboratory animal studies. Determine the strength of the evidence
for plausible mechanisms mediating in vivo effects at low doses. In addition, identify
any in vivo findings that are unexpected based on the in vitro literature.
Issue (2)Assess the degree to which ecological studies with wildlife are consistent with
laboratory studies in similar and different species. For example, determine the
similarity of exposure levels and types of responses seen in wildlife and laboratory
animals.
Issue (3)Discuss the degree to which the low doses of BPA used in laboratory animal studies
relate to the levels detected in human serum and tissues (including urine).
Issue (4)Assess the importance of life stage in the pharmacokinetics of BPA, levels of
exposure to BPA, and the health effects of BPA in animals and humans.
3. Findings submitted by the four breakout groups
The reports from the breakout groups are presented below. The four breakout groups conducted
a critical examination of the published research on BPA in relation to the four topics described
above. Each of the breakout groups identified areas of knowledge and research gaps and made
suggestions for future directions of research. In addition, each group identified which of the
following two categories applied to specific outcomes:
• “We are confident of the following”: this category applied when there were findings
reported in multiple papers from multiple labs that were in agreement. There should
have been no papers reporting conflicting findings, unless there were flaws in those
papers, in which case the flaw(s) should have been identified.
• “We believe the following to be likely but requiring confirmation”: This category
applied when there were multiple consistent findings from one lab, or there may have
been some conflicting reports along with reports of significant findings.
4. Levels of confidence for published BPA findings
The responses from the four different breakout groups were integrated together and organized
based on levels of confidence. The criterion for a statement being included in a category was
that there had to be consensus among all four of the breakout groups about the statement.
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4.1. Based on existing data we are confident of the following
4.1.1. Issue 1: In vitro mechanistic research—laboratory animal research
connection
1. In vitro studies have provided two routes of plausibility for low dose in vivo effects
of BPA. These include binding to nuclear estrogen receptors that regulate
transcription as well as estrogen receptors associated with the cell membrane that
promote calcium mobilization and intracellular signaling. Receptors associated with
the cell membrane are more sensitive to BPA than the nuclear receptors. Actions
mediated by membrane associated receptor signaling may underlie much of the low
dose BPA phenomena (effects have been reported at doses as low as 1 pM or 0.23
ppt). This increases the plausibility of effects at low doses, which are within the range
of environmentally relevant doses (human and wildlife levels of exposure).
2. In vitro mechanistic information has informed us that exposing tissues to only an
extremely narrow range of doses of BPA may lead to erroneous conclusions. Non-
monotonic dose–response curves are encountered frequently in basic
endocrinological research, and numerous examples have been reported for BPA
reviewed in Refs. [18,23,24]. Because of this animal experiments on unstudied
systems must avoid narrow dose ranges, especially the use of only a few very high
doses. Thus, testing one or two doses and concluding that there are no effects is
inappropriate. At somewhat higher doses than are required for estrogen receptor (ER)-
mediated responses, BPA also interacts with androgen and thyroid hormone receptors,
making predictions of effects at different doses very complex.
3. In vitro studies can dissect mechanisms of complicated effects observed in vivo. The
proposed potential mechanisms acting in vitro and in vivo are the same, involving
estrogen receptor mediated (nuclear- and membrane-associated) actions. However,
specific effects are dose and cell/tissue specific. In addition, there are in vivo processes
that are not reflective of currently known mechanisms that have been identified in
vitro. This is due to previously unknown mechanisms as well as the complexity (due
to interactions among cell and tissue types) of in vivo systems.
4.1.2. Issue 2: Wildlife—laboratory animal research connection
1. BPA is found in the environment: aquatic, terrestrial and air.
2. Studies of wildlife demonstrate estrogenic responses that are similar to responses seen
in laboratory animals. Specifically, reductions in spermatogenesis are seen in wildlife
at ecological concentrations of BPA, and these effects are also seen in controlled
laboratory studies with BPA. In addition, vitellogenin response is a common
biomarker in non-mammalian wildlife and laboratory species for BPA-induced
estrogen receptor activation as well as activation by other estrogens.
3. BPA exposure induces similar effects in reproductive systems in wildlife and
experimental animal model systems, but concentrations used in experiments
involving wildlife species are often higher than environmental exposures. There are
conditions in the environment, such as landfill leachates and effluent outflow that
cause episodic exposure of field populations to elevated doses of BPA.
4. Responses in a variety of vertebrate wildlife species are qualitatively consistent with
controlled laboratory studies with BPA. Thus, animals in the wild show evidence of
harm, and controlled laboratory studies with model aquatic animals (i.e., medaka,
zebrafish, and fathead minnows) are consistent with observations made in wildlife
species. Low dose effects of BPA (low ppb range) have been observed in many of
these animals.
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5. The similar effects observed in wildlife and laboratory animals exposed to BPA
predict that similar effects are also occurring in humans.
4.1.3. Issue 3: Laboratory animal research—human exposure connection
1. Human exposure to BPA is widespread.
2. Human exposure to BPA is variable, and exposure levels cover a broad range [central
tendency for unconjugated BPA: 0.3–4.4 ng ml−1 (ppb)] in tissues and fluids in
fetuses, children and adults.
3. Because the current published literature states that there is a linear relationship
between administered dose and circulating levels of BPA in animal studies, this allows
circulating levels at lower administered doses to be predicted in experimental animals
based on the results from studies in which higher doses were administered.
4. All of the currently published metabolic studies in rats predict circulating BPA levels
after acute low dose oral exposures at blood levels less than or equal to 2 ng ml−1
(ppb), which is the approximate median and mean unconjugated circulating BPA level
in humans. Therefore, the commonly reported circulating levels in humans exceed
the circulating levels extrapolated from acute exposure studies in laboratory animals.
5. BPA levels in the fetal mouse exposed to BPA by maternal delivery of 25 µg kg−1, a
dose that has produced adverse effects in multiple experiments, are well within the
range of unconjugated BPA levels observed in human fetal blood.
4.1.4. Issue 4: Life stage—relationship to exposure pharmacokinetics and
health effects
1. Sensitivity to endocrine disruptors, including BPA, varies extensively with life stage,
indicating that there are specific windows of increased sensitivity at multiple life
stages. Therefore, it is essential to assess the impact of life stage on the response to
BPA in studies involving wildlife, laboratory animals, and humans.
2. Developmental windows of susceptibility are comparable in vertebrate wildlife
species and laboratory animals.
3. BPA alters “epigenetic programming” of genes in experimental animals and wildlife
that results in persistent effects that are expressed later in life [25]. These
organizational effects (functional and structural) in response to exposure to low doses
of BPA during organogenesis persist into adulthood, long after the period of exposure
has ended. Specifically, prenatal and/or neonatal exposure to low doses of BPA results
in organizational changes in the prostate, breast, testis, mammary glands, body size,
brain structure and chemistry, and behavior of laboratory animals.
4. There are effects due to exposure in adulthood that occurs at low doses of BPA.
Substantial neurobehavioral effects and reproductive effects in both males and
females have been observed during adult exposures in laboratory animals.
5. Adult exposure studies cannot be presumed to predict the results of exposure during
development.
6. Life stage impacts the pharmacokinetics of BPA.
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4.2. We believe the following to be likely but require confirmation
4.2.1. Issue 1: In vitro mechanistic research—laboratory animal research
connection
1. BPA metabolism occurs in cell culture systems, and although there are differences
between cell types, there is less variability than in the entire animal. Metabolism is
an important issue for humans and wildlife field populations with large genetic
variability. Individual differences in BPA pharmacokinetics allow for underlying
variability within a population, and may allow for the identification of sensitive and
insensitive subpopulations.
2. The activity of various enzymes involved in drug, chemical, and hormone
metabolism, as well as protection against oxidative stress, are programmed by
hormone levels during sensitive periods in development. Developmental alterations
in hormonal programming (activation or inhibition) may thus affect metabolism of
BPA and other hormones and chemicals. Direct interaction of BPA with enzymes in
cells has only been reported at higher doses than expected for human exposures.
3. The set of genes regulated by BPA is expected to differ among doses. Therefore,
different doses of BPA do not produce different effects only due to a quantitative
difference in the expression of the same set of genes.
4. Differential expression of estrogen receptor subtypes (α/β; variant isoforms), and
protein–protein interactions (estrogen receptor homo- and hetero-dimer formation,
co-regulators, etc) modulate the cellular response to BPA. Direct actions of BPA on
intracellular signal transduction modulate some cellular responses, which are
similarly dependent on differential expression and protein–protein interactions.
5. Bioactive doses can be mathematically modeled, but further model refinement and
experimental confirmation is required.
6. Other mechanisms (androgen receptors, thyroid hormone receptors) may be relevant
for BPA action, but at higher doses than for estrogen responsive mechanisms.
4.2.2. Issue 2: Wildlife—laboratory animal research connection
1. The effects observed in laboratory animals could be present in wildlife, because the
low doses being studied in laboratory animals are now relevant to environmental
exposure levels of wildlife. The similarities in mechanisms that have been observed
between different species suggest that field populations will respond to the same low
levels.
2. Measurements of vitellogenin production in fish have established that there are
exogenous estrogenic signals in the their environment. BPA may be contributing to
this phenomenon as it enters natural water systems after leaching from landfills and
due to plastic debris in water.
3. Delayed spawning is seen in male and female fish, which may relate to observed
changes in estrous cyclicity in mammals in laboratory experiments.
4. In wildlife and laboratory studies, BPA induces alteration in steroid biosynthesis/
metabolism/excretion.
5. Wildlife residing in sediment is likely exposed to higher levels of BPA.
4.2.3. Issue 3: Laboratory animal research—human exposure connection
1. Human exposure is likely to be continuous, unlike exposure in most laboratory animal
studies of BPA pharmacokinetics.
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4.2.4. Issue 4: Life stage—relationship to exposure pharmacokinetics and
health effects
1. Clearance of BPA in the fetus is reduced compared to other life stages. Different
effects and metabolic clearance mechanisms are also observed in neonatal and adult
animals. Conjugation (glucuronidation) and other mechanisms of metabolic clearance
of BPA thus vary throughout life.
2. Exposure to BPA during different life stages differentially influences reproductive
cancer etiology and progression, and exposure during sensitive periods in
organogenesis may increase susceptibility to development of cancers in some organs,
such as the prostate and mammary glands.
3. Early life exposure to environmentally relevant BPA doses may result in persistent
adverse effects in humans.
4. The function of the immune system can be altered following adult exposure to BPA.
5. Effects on insulin metabolism occur following adult exposure.
4.3. Areas of uncertainty and suggestions for future research
4.3.1. Issue 1: In vitro mechanistic research—laboratory animal research
connection
1. Since BPA can act as an agonist or an antagonist in different tissues and against
different background physiological states, the specific co-regulators that mediated
these different responses of BPA need to be elucidated based on in vitro mechanistic
studies, which should be confirmed in vivo.
2. Research is needed on specific receptor sub-types (i.e., classical nuclear and non-
classical membrane-associated estrogen receptors) in relation to the potency of BPA
in different tissues.
3. The identification of multiple estrogen receptor genes and variants as well as different
co-regulators with different activities reveals that different levels of potency of BPA
could be obtained by complex interactions between these different components that
would not be predicted in homogeneous recombinant systems.
4.3.2. Issue 2: Wildlife—laboratory animal research connection
1. To directly relate the effects seen in wildlife with BPA exposure, biomonitoring data
are needed from wildlife. In addition to BPA levels, these studies should assay total
estrogenic and antiandrogenic activity from other contaminants.
2. There is a need to examine sensitive endpoints in wildlife that have been identified
in laboratory animals.
3. There are substantial amounts of plastic debris within marine and fresh water
ecosystems, and studies are needed to examine the impact of BPA in the environment
on aquatic organisms. Doses used in laboratory experiments involving wildlife should
reflect environmental exposures.
4. More studies need to be done with BPA in invertebrates, and a fundamental
understanding of estrogen action in invertebrates is required.
5. Studies should determine if amplification of BPA through the food chain occurs,
particularly under anaerobic or hypoxic conditions due to the lack of microbial or
photodegradation.
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6. Future research emphasis should be placed on populations of aquatic animals exposed
to landfill leachate and sewage effluent, as these are the primary point sources for
BPA exposure.
4.3.3. Issue 3: Laboratory animal research—human exposure connection
1. Even though there have been attempts to estimate daily human intake of BPA, these
estimates require many assumptions. The best measures we have to estimate whether
humans may be affected by current exposures to BPA are levels in blood (not exposure
levels), which can be related to blood levels in experimental animals after acute
exposures. Known sources of human exposure to BPA do not appear sufficient to
explain levels measured in human tissues and fluids.
2. While BPA is not persistent in the environment or in humans, biomonitoring surveys
indicate that exposure is continuous. This is problematic because acute animal
exposure studies are used to estimate daily human exposure to BPA, and at this time,
we are not aware of any studies that have examined BPA pharmacokinetics in animal
models following continuous low level exposures. Measurement of BPA levels in
serum and other body fluids suggests that either BPA intake is much higher than
accounted for, or that BPA can bioaccumulate in some conditions such as pregnancy,
or both. Research using both animal models, as well as epidemiology studies, are
needed to address these hypotheses, and this research needs to better mimic the
apparent continuous exposure of humans to BPA.
3. More comprehensive exposure and biomonitoring studies are needed, especially in
developing countries.
4. In both animal and human studies, internal exposure measures need to be related to
health effects. In particular, there is a need for epidemiological studies relating health
outcomes to BPA exposure, particularly during sensitive periods in development.
These studies should be based on hypotheses from findings in experimental animals.
This will require additional development of appropriate biomarkers in animal studies
that can be used in epidemiological research.
4.3.4. Issue 4: Life stage—relationship to exposure pharmacokinetics and
health effects
1. While there is a great need to continue studying prenatal and perinatal exposures in
laboratory animal studies, many organs and endpoints continue developing at later
stages (throughout puberty and adolescence). Additional studies are needed during
these later periods of development.
2. Additional research is needed regarding exposure to BPA in adulthood to determine
whether post-exposure effects are temporary or are permanent and associated with
subsequent age-related diseases.
3. Because aging adults lose repair mechanisms, metabolic enzymes, and imprinted
genes, the possibility that adult exposures (long-term, low level) can increase the risk
of cancers and other conditions during aging should be addressed with additional
human research and the development of appropriate animal models.
4. Epigenetics should be examined as a potential mechanism mediating developmental
effects as well as the trans-generational effects of BPA and other contaminants.
Potential effects of adult exposures also need to be examined in relation to disruption
of epigenetic changes that occur normally during aging.
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5. Trans- and multi-generational effects of BPA must be examined in laboratory animals
and humans.
6. There is a need for studies that involve collection of human blood and urine from
humans at several life stages, with specific emphasis on infants and young children
and continued monitoring throughout adulthood. Additionally, there is a need to
characterize the basis for the variability in BPA levels in studies examining both
human urine and serum.
7. There is a need for research on the genetic basis for differences in susceptibility to
BPA and other contaminants.
8. Studies are needed on comparative BPA pharmacokinetics in invertebrates and
vertebrates (non-human primates included).
9. There is a need to measure total endocrine disrupter load in humans and wildlife.
Therefore, biomarkers of endocrine disrupter exposure are necessary.
10. There is a need for more research directed at examining human exposure,
pharmacokinetics and health effects of selected BPA precursors (i.e., BADGE,
BISGMA, and BIS-DMA) and metabolites (e.g., halogenated BPAs).
11. There is a need for more studies focused on identification of other (non-estrogen-
receptor mediated) mechanisms of action of BPA.
12. Effects of chemicals on the immune system are life stage dependent, and identifying
the life stage dependency for BPA effects on the immune system is necessary. In
addition, studies examining BPA effects on the immune system in wildlife are
necessary.
5. Conclusions
The published scientific literature on human and animal exposure to low doses of BPA in
relation to in vitro mechanistic studies reveals that human exposure to BPA is within the range
that is predicted to be biologically active in over 95% of people sampled. The wide range of
adverse effects of low doses of BPA in laboratory animals exposed both during development
and in adulthood is a great cause for concern with regard to the potential for similar adverse
effects in humans. Recent trends in human diseases relate to adverse effects observed in
experimental animals exposed to low doses of BPA. Specific examples include: the increase
in prostate and breast cancer, uro-genital abnormalities in male babies, a decline in semen
quality in men, early onset of puberty in girls, metabolic disorders including insulin resistant
(type 2) diabetes and obesity, and neurobehavioral problems such as attention deficit
hyperactivity disorder (ADHD).
There is extensive evidence that outcomes may not become apparent until long after BPA
exposure during development has occurred. The issue of a very long latency for effects in
utero to be observed is referred to as the developmental origins of adult health and disease
(DOHaD) hypothesis. These developmental effects are irreversible and can occur due to low
dose exposure during brief sensitive periods in development, even though no BPA may be
detected when the damage or disease is expressed. However, this does not diminish our concern
for adult exposure, where many adverse outcomes are observed while exposure is occurring.
Concern regarding exposure throughout life is based on evidence that there is chronic, low
level exposure of virtually everyone in developed countries to BPA. These findings indicate
that acute studies in animals, particularly traditional toxicological studies that only involve the
use of high doses of BPA, do not reflect the situation in humans.
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The fact that very few epidemiological studies have been conducted to address the issue of the
potential for BPA to impact human health is a concern, and more research is clearly needed.
This also applies to wildlife, both aquatic and terrestrial. The formulation of hypotheses for
the epidemiological and ecological studies can be greatly facilitated by the extensive evidence
from laboratory animal studies, particularly when common mechanisms that could plausibly
mediate the responses are known to be very similar in the laboratory animal models, wildlife
and humans.
Abbreviations
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BIS-DMA bisphenol A dimethacrylate




Meeting support was provided by NIEHS and NIDCR, NIH/DHHS, the US-EPA and Commonweal. We thank Paul
French for assistance with the meeting in web site and Albert Kingman for advice during preparation of the manuscript.
This manuscript does not reflect US-EPA, USGS or NIH agency policy. FvS is supported by NIH grant ES11283.
References
1. Vandenberg LN, Hauser R, Marcus M, Olea N, Welshons WV. Human exposure to bisphenol A (BPA).
Reprod Toxicol 2007;24:139–177. [PubMed: 17825522]
2. Wetherill YB, Akingbemi B, Kanno J, McLachlan JA, Nadal A, Sonnenschein C, et al. In vitro
molecular mechanisms of bisphenol A action. Reprod Toxicol 2007;24:178–198. [PubMed:
17628395]
3. Richter CR, Birnbaum LS, Farabollini F, Newbold RR, Rubin BS, Talsness CE, et al. In vivo effects
of bisphenol A in laboratory rodent studies. Reprod Toxicol 2007;24:199–224. [PubMed: 17683900]
4. Crain DA, Eriksen M, Iguchi T, Jobling S, Laufer H, LeBlanc GA, et al. An ecological assessment of
bisphenol A: evidence from comparative biology. Reprod Toxicol 2007;24:225–239. [PubMed:
17604601]
5. Keri RA, Ho S-M, Hunt PA, Knudsen KE, Soto AM, Prins GS. An evaluation of evidence for the
earcinogenic activity of bisphenol A. Reprod Toxicol 2007;24:240–252. [PubMed: 17706921]
6. NTP. Raleigh; NC: 2001 [Access data: June 8, 2007]. Final Report of the Endocrine Disruptors Low
Dose Peer Review Panel.
http://ntp.niehs.nih.gov/index.cfm?objectid=06F5CE98-E82F-8182-7FA81C02D3690D47ml
7. IRIS. Bisphenol A (CASRN 80-05-7). US-EPA Integrated Risk Information System Substance File.
1988 [Access data: June 8, 2007]. http://www.epa.gov/iris/subst/0356.htm
8. Nagel SC, vom Saal FS, Thayer KA, Dhar MG, Boechler M, Welshons WV. Relative binding affinity-
serum modified access (RBA-SMA) assay predicts the relative in vivo bioactivity of the xenoestrogens
bisphenol A and octylphenol. Environ Health Perspect 1997;105(1):70–76. [PubMed: 9074884]
9. Colerangle JB, Roy D. Profound effects of the weak environmental estrogen-like chemical bisphenol
A on the growth of the mammary gland of Noble rats. J Steroid Biochem Mol Biol 1997;60(1–2):153–
160. [PubMed: 9182870]
10. Steinmetz R, Brown NG, Allen DL, Bigsby RM, Ben-Jonathan N. The environmental estrogen
bisphenol A stimulates prolactin release in vitro and in vivo. Endocrinol 1997;138(5):1780–1786.
11. Burridge E. Bisphenol A: product profile. Eur Chem News 2003:17.
vom Saal et al. Page 13













12. Olea N, Pulgar R, Perez P, Olea-Serrano F, Rivas A, Novillo-Fertrell A, et al. Estrogenicity of resin-
based composites and sealants used in dentistry. Environ Health Perspect 1996;104(3):298–305.
[PubMed: 8919768]
13. Moore, C. Synthetic polymers in the marine environment: what we know, what we need to know,
what can be done?. In: Ragaini, RC., editor. Proceedings of Conference: International Seminar on
Nuclear War and Planetary Emergencies, 36th Session; August 2006; Erice, Sicily. Singapore: World
Scientific Publishers; in press
14. Coors A, Jones PD, Giesy JP, Ratte HT. Removal of estrogenic activity from municipal waste landfill
leachate assessed with a bioassay based on reporter gene expression. Environ Sci Technol 2003;37
(15):3430–3434. [PubMed: 12966991]
15. Kawagoshi Y, Fujita Y, Kishi I, Fukunaga I. Estrogenic chemicals and estrogenic activity in leachate
from municipal waste landfill determined by yeast two-hybrid assay. J Environ Monit 2003;5(2):
269–274. [PubMed: 12729267]
16. Rudel RA, Brody JG, Spengler JD, Vallarino J, Geno PW, Sun G, et al. Identification of selected
hormonally active agents and animal mammary carcinogens in commercial and residential air and
dust samples. J Air Waste Manage Assoc 2001;51:499–513.
17. Dodds EC, Lawson W. Synthetic oestrogenic agents without the phenanthrene nucleus. Nature
1936;137:996.
18. Welshons WV, Nagel SC, vomSaal FS. Large effects from small exposures. III. Endocrine
mechanisms mediating effects of bisphenol A at levels of human exposure. Endocrinology 2006;147
Suppl. 6:S56–S69. [PubMed: 16690810]
19. Quesada I, Fuentes E, Viso-Leon MC, Soria B, Ripoll C, Nadal A. Low doses of the endocrine
disruptor bisphenol-A and the native hormone 17beta-estradiol rapidly activate transcription factor
CREB. FASEB J 2002;16(12):1671–1673. [PubMed: 12207000]
20. Walsh DE, Dockery P, Doolan CM. Estrogen receptor independent rapid non-genomic effects of
environmental estrogens on [CA2+]i in human breast cancer cells. Mol Cell Endocrinol 2005;230(1–
2):23–30. [PubMed: 15664448]
21. Wozniak AL, Bulayeva NN, Watson CS. Xenoestrogens at picomolar to nanomolar concentrations
trigger membrane estrogen receptor-a mediated Ca++ fluxes and prolactin release in GH3/B6
pituitary tumor cells. Environ Health Perspect 2005;113:431–439. [PubMed: 15811834]
22. Zsarnovszky A, Le HH, Wang HS, Belcher SM. Ontogeny of rapid estrogen-mediated extracellular
signal-regulated kinase signaling in the rat cerebellar cortex: potent nongenomic agonist and
endocrine disrupting activity of the xenoestrogen bisphenol A. Endocrinol 2005;146(12):5388–5396.
23. vom Saal FS, Welshons WV. Large effects from small exposures. II. The importance of positive
controls in low-dose research on bisphenol A. Environ Res 2006;100:50–76. [PubMed: 16256977]
24. Welshons WV, Thayer KA, Judy BM, Taylor JA, Curran EM, vom Saal FS. Large effects from small
exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity. Environ
Health Perspect 2003;111(8):994–1006. [PubMed: 12826473]
25. Ho SM, Tang WY, Belmonte de Frausto J, Prins GS. Developmental exposure to estradiol and
bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates
phosphodiesterase type 4 variant 4. Cancer Res 2006;66(11):5624–5632. [PubMed: 16740699]
vom Saal et al. Page 14
Reprod Toxicol. Author manuscript; available in PMC 2010 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
